Clinical Trial Update: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization [Phase 3]

View source ↗

Summary

This is a multicenter Phase 3 trial evaluating SPM 927 as adjunctive therapy for partial seizures with or without secondary generalization. The study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Seizures with or Without Secondary Generalization

Drugs mentioned

• SPM 927 (SPM 927)

Snippet

Sponsor: UCB Pharma | Conditions: Partial Seizures With or Without Secondary Generalization | Phase 3 | Status: COMPLETED